Wuhan Thalys Med Tech Co Ltd (603716) - Net Assets
Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) has net assets worth CN¥986.39 Million CNY (≈ $144.34 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.74 Billion ≈ $254.54 Million USD) and total liabilities (CN¥753.10 Million ≈ $110.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Wuhan Thalys Med Tech Co Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥986.39 Million |
| % of Total Assets | 56.71% |
| Annual Growth Rate | 9.5% |
| 5-Year Change | -48.1% |
| 10-Year Change | 5.26% |
| Growth Volatility | 28.14 |
Wuhan Thalys Med Tech Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Wuhan Thalys Med Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. See Wuhan Thalys Med Tech Co Ltd (603716) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Wuhan Thalys Med Tech Co Ltd (2011–2025)
The table below shows the annual net assets of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025. For live valuation and market cap data, see Wuhan Thalys Med Tech Co Ltd (603716) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥904.49 Million ≈ $132.35 Million |
-5.98% |
| 2024-12-31 | CN¥962.04 Million ≈ $140.78 Million |
-26.82% |
| 2023-12-31 | CN¥1.31 Billion ≈ $192.38 Million |
-12.18% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.05 Million |
-14.11% |
| 2021-12-31 | CN¥1.74 Billion ≈ $255.04 Million |
-3.31% |
| 2020-12-31 | CN¥1.80 Billion ≈ $263.77 Million |
+11.20% |
| 2019-12-31 | CN¥1.62 Billion ≈ $237.21 Million |
-0.28% |
| 2018-12-31 | CN¥1.63 Billion ≈ $237.88 Million |
+61.95% |
| 2017-12-31 | CN¥1.00 Billion ≈ $146.88 Million |
+16.81% |
| 2016-12-31 | CN¥859.29 Million ≈ $125.74 Million |
+82.71% |
| 2015-12-31 | CN¥470.30 Million ≈ $68.82 Million |
+15.84% |
| 2014-12-31 | CN¥405.99 Million ≈ $59.41 Million |
+17.35% |
| 2013-12-31 | CN¥345.97 Million ≈ $50.63 Million |
+16.68% |
| 2012-12-31 | CN¥296.50 Million ≈ $43.39 Million |
+16.78% |
| 2011-12-31 | CN¥253.90 Million ≈ $37.15 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan Thalys Med Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 312.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.11 Billion | 117.18% |
| Total Equity | CN¥944.69 Million | 100.00% |
Wuhan Thalys Med Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Wuhan Thalys Med Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
$512.99 Million |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
$513.07 Million |
|
Greenlight Capital Re Ltd
NASDAQ:GLRE
|
$513.08 Million |
|
Korea Electric Terminal
KO:025540
|
$513.42 Million |
|
Zhejiang Huakang Pharmaceutical Co Ltd
SHG:605077
|
$512.64 Million |
|
Hefei Lifeon Pharmaceutical Co Ltd
SHE:003020
|
$512.62 Million |
|
Surfilter Network Technology Co Ltd
SHE:300311
|
$512.58 Million |
|
Kearny Financial Corp
NASDAQ:KRNY
|
$512.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan Thalys Med Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 934,292,086 to 944,688,923, a change of 10,396,837 (1.1%).
- Net loss of 207,283,948 reduced equity.
- Dividend payments of 18,557,541 reduced retained earnings.
- Other factors increased equity by 236,238,326.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-207.28 Million | -21.94% |
| Dividends Paid | CN¥18.56 Million | -1.96% |
| Other Changes | CN¥236.24 Million | +25.01% |
| Total Change | CN¥- | 1.11% |
Book Value vs Market Value Analysis
This analysis compares Wuhan Thalys Med Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.02x to 3.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.93 | CN¥15.52 | x |
| 2012-12-31 | CN¥2.25 | CN¥15.52 | x |
| 2013-12-31 | CN¥2.55 | CN¥15.52 | x |
| 2014-12-31 | CN¥2.99 | CN¥15.52 | x |
| 2015-12-31 | CN¥3.45 | CN¥15.52 | x |
| 2016-12-31 | CN¥4.75 | CN¥15.52 | x |
| 2017-12-31 | CN¥5.27 | CN¥15.52 | x |
| 2018-12-31 | CN¥7.91 | CN¥15.52 | x |
| 2019-12-31 | CN¥7.55 | CN¥15.52 | x |
| 2020-12-31 | CN¥8.30 | CN¥15.52 | x |
| 2021-12-31 | CN¥7.89 | CN¥15.52 | x |
| 2022-12-31 | CN¥7.21 | CN¥15.52 | x |
| 2023-12-31 | CN¥6.26 | CN¥15.52 | x |
| 2024-12-31 | CN¥4.87 | CN¥15.52 | x |
| 2025-12-31 | CN¥4.49 | CN¥15.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan Thalys Med Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.25%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.91x
- Recent ROE (-21.94%) is below the historical average (2.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 14.99% | 19.50% | 0.62x | 1.25x | CN¥12.58 Million |
| 2012 | 13.05% | 13.54% | 0.73x | 1.32x | CN¥8.96 Million |
| 2013 | 14.32% | 12.51% | 0.90x | 1.28x | CN¥14.79 Million |
| 2014 | 14.16% | 12.70% | 0.83x | 1.35x | CN¥16.59 Million |
| 2015 | 13.34% | 11.60% | 0.80x | 1.44x | CN¥15.39 Million |
| 2016 | 8.17% | 10.99% | 0.57x | 1.30x | CN¥-15.44 Million |
| 2017 | 10.05% | 10.20% | 0.59x | 1.68x | CN¥508.77K |
| 2018 | 6.19% | 7.15% | 0.51x | 1.70x | CN¥-57.92 Million |
| 2019 | 7.41% | 6.03% | 0.61x | 2.02x | CN¥-38.50 Million |
| 2020 | 3.49% | 2.71% | 0.54x | 2.37x | CN¥-107.20 Million |
| 2021 | -3.17% | -1.90% | 0.61x | 2.75x | CN¥-205.71 Million |
| 2022 | -10.96% | -6.66% | 0.58x | 2.81x | CN¥-294.03 Million |
| 2023 | -13.10% | -7.90% | 0.60x | 2.76x | CN¥-279.66 Million |
| 2024 | -22.40% | -11.56% | 0.64x | 3.03x | CN¥-302.67 Million |
| 2025 | -21.94% | -19.25% | 0.60x | 1.91x | CN¥-301.75 Million |
Industry Comparison
This section compares Wuhan Thalys Med Tech Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,578,164,998
- Average return on equity (ROE) among peers: 23.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan Thalys Med Tech Co Ltd (603716) | CN¥986.39 Million | 14.99% | 0.76x | $512.79 Million |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $406.61 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $110.32 Million | 15.56% | 0.62x | $1.67 Billion |
| Hangzhou Tigermed Consulting (300347) | $146.03 Million | 32.73% | 0.28x | $4.33 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $385.67 Million | 35.53% | 0.12x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $470.71 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.53 Billion | 10.85% | 0.25x | $742.36 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $2.53 Billion | 14.31% | 0.13x | $505.18 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.17 Billion |
| Amoy Diagnostics Co Ltd (300685) | $1.70 Billion | 15.35% | 0.14x | $959.68 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.25 Billion | 8.85% | 0.18x | $507.55 Million |
About Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more